Cocrystal Pharma
COCP
24 hedge funds and large institutions have $1.44M invested in Cocrystal Pharma in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
20% more funds holding
Funds holding: 20 → 24 (+4)
14% more capital invested
Capital invested by funds: $1.27M → $1.44M (+$171K)
0.08% less ownership
Funds ownership: 7.07% → 7% (-0.08%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$20K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10.4K |
| 3 |
Morgan Stanley
New York
|
+$10.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.26K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$51.4K |
| 2 |
Renaissance Technologies
New York
|
-$8.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.83K |
| 4 |
JP Morgan Chase
New York
|
-$304 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$58 |
COCP Hedge Fund Activity: Q4 2024 in Review
24 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q4 2024, worth a combined $1.44M — up 14% from $1.27M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new COCP positions and 1 closed out — a net gain of 4 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Velan Capital Investment Management, opening a new position worth an estimated $20K. The largest seller was Susquehanna International Group, cutting an estimated $51.4K.
- 24 institutional investors held Cocrystal Pharma (COCP) as of Q4 2024, up from 20 in Q3 2024.
- Funds reported $1.44M of Cocrystal Pharma stock for Q4 2024, up 14% quarter-over-quarter.
- 5 funds opened new Cocrystal Pharma positions in Q4 2024 and 1 closed out, a net change of +4 holders.
- The largest Cocrystal Pharma buyer in Q4 2024 was Velan Capital Investment Management, an estimated $20K added.
- The largest Cocrystal Pharma seller in Q4 2024 was Susquehanna International Group, an estimated $51.4K sold.
Based on aggregated 13F filings for Q4 2024.